MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202511033054 A) filed by Indian Institute Of Technology, Kanpur, Uttar Pradesh, on April 3, 2025, for 'optimized transgene and engineered capsid for aav based gene therapy of diabetes.'
Inventor(s) include Jayandharan Giridhara Rao; Ramkumar Rajendiran; Subhajit Pathak; and Sai Prasad Pydi.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "In accordance with an embodiment of the present disclosure, a method for optimized transgene and engineered capsid for AAV-based gene therapy of diabetes is disclosed. This method involves the use of a codon-optimized human FGF21 gene delivered by an engineered AAV8 vector, which includes specific capsid modifications such as Neddylation-site mutations (e.g., K31Q and K61Q) to enhance hepatocyte transduction and transgene expression. Additionally, the strategy may incorporate the use of muscle-targeting elements, such as AAV9 vectors encoding miR-411, to mitigate potential adverse effects on skeletal muscle, thereby ensuring a comprehensive therapeutic effect on both glycemic control and muscle integrity."
Disclaimer: Curated by HT Syndication.
